BRKR logo

Bruker Corporation (BRKR)

$62

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on BRKR

Market cap

$9.45B

EPS

-0.7

P/E ratio

--

Price to sales

2.56

Dividend yield

0.323%

Beta

1.222556

Price on BRKR

Previous close

$60.74

Today's open

$60.66

Day's range

$60.55 - $63.39

52 week range

$32.37 - $66.98

Profile about BRKR

CEO

Frank H. Laukien

Employees

11396

Headquarters

Billerica, MA

Exchange

Nasdaq Global Select

Shares outstanding

152359316

Issue type

Common Stock

BRKR industries and sectors

Healthcare

Biotechnology & Life Sciences

News on BRKR

Bruker Announces Date and Time of Third Quarter 2026 Earnings Release and Webcast

BILLERICA, Mass.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced it will report third quarter 2026 financial results before market opening on Wednesday, November 4, 2026. The Company will host a conference call and webcast at 8:30 a.m. Eastern Daylight Time to discuss the results and current business trends. To listen to the webcast, investors can go to https://ir.bruker.com and click on the “Q3 2026 Earnings Webcast” hyperlink in the “Events & Presentations” section. A.

news source

Business Wire • Oct 20, 2026

news preview

Bruker Gains 66.3% in a Year: What's Driving the Rally?

BRKR shares surge 66.3% in a year, fueled by strong demand in mass spectrometry and biopharma, despite restructuring challenges and currency headwinds.

news source

Zacks Investment Research • Oct 8, 2026

news preview

Untargeted timsTOF Mass Spectrometry Enables Discovery and Mapping of Draft Atlas of the Human Plasma Proteome at Proteoform Resolution

BERLIN--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) announced a seminal bioRxiv preprint, describing a draft atlas of the human plasma proteome at isoform, or proteoform, resolution. The study was conducted by principal investigator Markus Ralser at Charité – Universitätsmedizin Berlin and collaborators. The preprint “A draft atlas of the human plasma proteome at isoform resolution” was posted on September 28, 2026 at https://doi.org/10.64898/2026.09.26.754256. By combining intact protei.

news source

Business Wire • Oct 6, 2026

news preview

Why Bruker (BRKR) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

news source

Zacks Investment Research • Oct 2, 2026

news preview

Bruker Advances Functional Proteomics with Novel timsUltra AIP and timsOmni Workflows for Drug Discovery & Development and Disease Biology Research

SINGAPORE--(BUSINESS WIRE)---- $BRKR #BRKR--At the Human Proteome Organization World Congress 2026, Bruker Corporation (Nasdaq: BRKR) today announced unique new timsUltra AIP and timsOmni workflows for deeper protein-sequence coverage, targeted validation, mobility-resolved glycopeptide characterization, structural proteomics, and oligonucleotide analysis. Multi-enzyme dia-PASEF provides additional peptide information for investigations of isoforms and proteoforms, while ProteoScape workflows connect PASEF dis.

news source

Business Wire • Sep 28, 2026

news preview

Bruker Sees AI-Fueled Semiconductor Demand, Targets Critical Q4 Revenue Rebound

Bruker NASDAQ: BRKR CFO Gerald Herman said the company's second-quarter results reflected stronger-than-expected organic order bookings and earnings per share, while revenue came in later than anticipated. He attributed the revenue timing primarily to a mixed demand environment and shipment timing, including semiconductor-metrology orders that are expected to shift into the fourth quarter.

news source

MarketBeat • Sep 26, 2026

news preview

Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Bruker Corporation (BRKR) Presents at Bank of America Global Healthcare Conference 2026 Transcript

news source

Seeking Alpha • Sep 22, 2026

news preview

Bruker Receives Order for High-Field NMR Systems for Major Upgrade of Magnetic Resonance Research Infrastructure at UC Berkeley

BERKELEY, Calif.--(BUSINESS WIRE)---- $BRKR #BRKR--Bruker Corporation (Nasdaq: BRKR) today announced a multi-system order from the University of California, Berkeley for high-field Nuclear Magnetic Resonance (NMR) instrumentation at the Pines Magnetic Resonance Center. The investment will enhance access to next-generation NMR technologies, including 800 MHz–class instrumentation. These capabilities strengthen research in chemistry, materials science, structural biology, and related fields across UC Berkeley an.

news source

Business Wire • Sep 21, 2026

news preview

Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

Bruker Corporation (BRKR) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript

news source

Seeking Alpha • Sep 16, 2026

news preview

Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

Bruker Corporation (BRKR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript

news source

Seeking Alpha • Sep 9, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Bruker Corporation

Open an M1 investment account to buy and sell Bruker Corporation commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in BRKR on M1